NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31

NEKTAR THERAPEUTICS

Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Aug 14, 2026

$36.64+0.86 (+2.40%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

NEKTAR THERAPEUTICS income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	55	98	90	92	102	153	115	1,193	308	165	231	201	149	81	71	159	72
Cost of Revenue	0	31	34	22	25	19	21	24	31	30	34	29	39	30	22	26	31
Gross Profit	55	68	56	70	77	133	93	1,169	277	135	197	172	110	51	50	133	41
Research & Development	117	121	114	218	400	409	435	400	268	204	183	148	190	149	127	108	95
General & Administrative	69	77	77	92	123	105	99	81	52	44	43	41	41	42	47	41	41
Total Costs & Expenses	195	204	354	468	548	578	555	505	367	278	260	217	269	222	195	187	167
Operating Income	-140	-105	-264	-376	-446	-425	-440	688	-60	-113	-29	-16	-120	-141	-124	-28	-95
Interest Expense	–	–	–	0	0	6.85	21	22	22	22	18	18	18	15	10	11	12
Interest & Investment Income	10	15	19	6.78	2.73	–	–	–	–	–	–	–	0.73	2.32	2.24	1.55	3.69
Income from Equity Investments	-8.73	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-15	-14	-13	11	-77	-19	-0.02	-5.21	-36	-40	-51	-38	-40	-30	-9.02	-8.80	-7.64
Merger & Restructuring Charges	9.33	16	52	136	0	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	4.44	8.33	77	66	0	0	–	–	–	–	0	–	0	1.68	0	13	0
Gain (Loss) on Sale of Assets	–	0	-1.30	3.33	0	0	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-164	-119	-276	-365	-523	-444	-440	683	-96	-153	-81	-54	-160	-171	-133	-37	-103
Income Tax Expense	-0.14	-0.24	-0.20	3.22	0.56	0.49	0.61	1.41	0.62	0.88	0.51	-0.51	2.25	0.41	1.02	0.88	-0.25
Net Income incl. Noncontrolling Interests	-164	-119	-276	-368	-524	-444	-441	681	-97	-154	–	–	–	–	–	–	–
Net Income	-164	-119	-276	-368	-524	-444	-441	681	-97	-154	-81	-54	-162	-172	-134	-38	-103
EPS (Basic)(per share)	-9.73	-8.68	-21.75	-29.55	-42.90	-37.35	-37.80	60.30	-9.30	-16.50	-9.15	-6.30	-21.00	-22.50	-17.85	-6.00	-16.65
EPS (Diluted)(per share)	-9.73	-8.68	-21.75	-29.55	-42.90	-37.35	-37.80	56.70	-9.30	-16.50	-9.15	-6.30	-21.00	-22.50	-17.85	-6.00	-16.65
Shares Outstanding (Basic, Weighted)(shares)	17	14	13	12	12	12	12	11	10	9.31	8.83	8.46	7.72	7.65	7.53	–	–
Shares Outstanding (Diluted, Weighted)(shares)	17	14	13	12	12	12	12	12	10	9.31	8.83	8.46	7.72	7.65	7.53	–	–
EBITDA	-139	-101	-257	-364	-433	-413	-429	697	-47	-100	-18	-3.56	-106	-127	-109	-12	-80

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 100.0%
Operating margin: -253.7%
Net margin: -297.1%
Return on equity, FY2025: -217.9%

Financial strength

Current ratio: 10.42
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 55.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –